An Open Label, Long Term Safety Study of SD-809 ER in Patients With Chorea Associated With Huntington Disease

Trial Profile

An Open Label, Long Term Safety Study of SD-809 ER in Patients With Chorea Associated With Huntington Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Chorea; Huntington's disease
  • Focus Adverse reactions; Proof of concept; Registrational
  • Acronyms ARC-HD; ARC-HD Switch
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 Results (n=37) assessing the long-term tolerability of deutetrabenazine [SD 809] in patients with Huntington's disease who were switching from tetrabenazine, were published in the JAMA Neurology.
    • 11 Jul 2017 According to a Teva Pharmaceutical, results from the single-arm, switch cohort from this study were published in JAMA Neurology.
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top